Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

The imaging provider RadNet aims to acquire iCad and its artificial intelligence-powered mammography software—with plans to ...

Like Johnson & Johnson did during its earnings call the day before, Abbott estimated that global tariffs would end up costing ...

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. | Novartis has terminated a phase 2 trial evaluating an ...

Essa Pharma is facing a call to wind down operations. Soleus Capital Management, one of the company’s largest shareholders, ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

The Trump administration is freezing more than $2.2 billion in funding to Harvard University after the school defied the ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...